<DOC>
	<DOCNO>NCT00362635</DOCNO>
	<brief_summary>The purpose study compare efficacy safety 48-week treatment Clevudine 30 mg qd versus lamivudine 100 mg qd chronic hepatitis B infection .</brief_summary>
	<brief_title>Compare Efficacy Safety 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg CHB Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Patient 18 60 , inclusive . 2 . Patient HBV DNA positive DNA level screen &gt; = 3 x 1,000,000 copies/mL . 3 . Patient document HBsAg positive &gt; 6 month HBeAg positive . 4 . Patient AST ALT level &gt; = 1 time &lt; = 10 time upper limit normal ( x ULN ) . 5 . Patient bilirubin level &lt; = 1.5 x ULN bilirubin level &gt; 1.5 x ULN diagnosis Gilbert 's disease conjugate bilirubin within normal limit . 6 . Women childbearing age must negative urine ( bHCG ) pregnancy test start trial treatment . 7 . Patient able give write informed consent prior study start comply study requirement . 1 . Patient currently receive antiviral , immunomodulatory corticosteroid therapy . 2 . Patients previously treat lamivudine , lobucavir , adefovir , famciclovir , investigational nucleoside HBV infection . 3 . Previous treatment interferon must end least 6 month prior screen visit . 4 . Patient history ascites , variceal hemorrhage hepatic encephalopathy . 5 . Patient coinfected HCV HIV . 6 . Patient evidence decompensated cirrhosis hepatocellular carcinoma ( alpha fetoprotein ) . 7 . Patient pregnant breastfeeding . 8 . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . For male , condom use . Females must surgically sterile ( via hysterectomy bilateral tubal ligation ) , postmenopausal , use least medically acceptable barrier method contraception ( i.e. , IUD , barrier method spermicide abstinence ) . 9 . Patient clinically relevant history abuse alcohol drug . 10 . Patient significant gastrointestinal , renal , hepatic ( decompensated ) , bronchopulmonary , neurological , cardiovascular , oncologic allergic disease . 11 . Subjects currently participate another investigational study take investigational drug within last 4 week prior Screening Visit . 12 . Subjects take traditional Chinese medication , take traditional Chinese medication within last 2 week prior Screening Visit . 13 . Any criterion , , opinion investigator , suggest subject would compliant study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>